Steven J Ross1, Islam Y Elgendy1, Anthony A Bavry2,3. 1. Department of Medicine, University of Florida, Gainesville, FL, USA. 2. Department of Medicine, University of Florida, Gainesville, FL, USA. anthony.bavry@va.gov. 3. Medical Service, Cardiology Section (111D), North Florida/South Georgia Veterans Health System (Malcom Randall Veterans Administration Medical Center), 1601 SW Archer Road, Gainesville, FL, 32608, USA. anthony.bavry@va.gov.
Abstract
PURPOSE OF REVIEW: Nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used medications worldwide. There has been growing concern regarding the cardiovascular risks associated with NSAID use (both selective cyclooxygenase [COX]-2 inhibitors and nonselective NSAIDs). This review will examine the evidence pertaining to cardiovascular safety and bleeding risk related to nonaspirin NSAIDs. RECENT FINDINGS: Earlier studies exposed the cardiovascular risks associated with use of selective COX-2 inhibitors; however, further studies have shown that even nonselective COX inhibition may lead to an increased risk of cardiovascular events. Data have also suggested that nonaspirin NSAIDs carry a higher bleeding risk in patients on antithrombotic therapy. Nonaspirin NSAIDs may confer an increased risk of both adverse cardiovascular outcomes and bleeding complications, regardless of COX selectivity and duration of use. Thus, it remains important to limit their use whenever possible, especially in patients with established cardiovascular disease.
PURPOSE OF REVIEW: Nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used medications worldwide. There has been growing concern regarding the cardiovascular risks associated with NSAID use (both selective cyclooxygenase [COX]-2 inhibitors and nonselective NSAIDs). This review will examine the evidence pertaining to cardiovascular safety and bleeding risk related to nonaspirin NSAIDs. RECENT FINDINGS: Earlier studies exposed the cardiovascular risks associated with use of selective COX-2 inhibitors; however, further studies have shown that even nonselective COX inhibition may lead to an increased risk of cardiovascular events. Data have also suggested that nonaspirin NSAIDs carry a higher bleeding risk in patients on antithrombotic therapy. Nonaspirin NSAIDs may confer an increased risk of both adverse cardiovascular outcomes and bleeding complications, regardless of COX selectivity and duration of use. Thus, it remains important to limit their use whenever possible, especially in patients with established cardiovascular disease.
Authors: Michael E Farkouh; Howard Kirshner; Robert A Harrington; Sean Ruland; Freek W A Verheugt; Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Alberto Gimona; Patrice Matchaba; Christopher J Hawkey; James H Chesebro Journal: Lancet Date: 2004 Aug 21-27 Impact factor: 79.321
Authors: Emil Loldrup Fosbøl; Fredrik Folke; Søren Jacobsen; Jeppe N Rasmussen; Rikke Sørensen; Tina Ken Schramm; Søren S Andersen; Søren Rasmussen; Henrik Enghusen Poulsen; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason Journal: Circ Cardiovasc Qual Outcomes Date: 2010-06-08
Authors: Nancy A Nussmeier; Andrew A Whelton; Mark T Brown; Richard M Langford; Andreas Hoeft; Joel L Parlow; Steven W Boyce; Kenneth M Verburg Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245
Authors: Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245
Authors: F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis Journal: JAMA Date: 2000-09-13 Impact factor: 56.272
Authors: F Salvo; A Fourrier-Réglat; F Bazin; P Robinson; N Riera-Guardia; M Haag; A P Caputi; N Moore; M C Sturkenboom; A Pariente Journal: Clin Pharmacol Ther Date: 2011-04-06 Impact factor: 6.875
Authors: John A Baron; Robert S Sandler; Robert S Bresalier; Angel Lanas; Dion G Morton; Robert Riddell; Erik R Iverson; David L Demets Journal: Lancet Date: 2008-10-14 Impact factor: 79.321
Authors: M E Farkouh; J D Greenberg; R V Jeger; K Ramanathan; F W A Verheugt; J H Chesebro; H Kirshner; J S Hochman; C L Lay; S Ruland; B Mellein; P T Matchaba; V Fuster; S B Abramson Journal: Ann Rheum Dis Date: 2007-04-05 Impact factor: 19.103
Authors: Azizah M Malebari; Ahdab N Khayyat; Ruba A Mahdali; Jumana S Alamoudi; Bushra Y Alsayed; Samar A Alrasheed Journal: Saudi Med J Date: 2020-08 Impact factor: 1.484
Authors: Che Suraya Zin; Nor Ilyani Nazar; Norny Syafinaz Rahman; Nor Elina Alias; Wan Rohaidah Ahmad; Nurul Sahida Rani; Mary Suma Cardosa; Kim Swan Ng; Felicia Loh Ye Journal: J Pain Res Date: 2018-09-20 Impact factor: 3.133